Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA007450 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA007450, RRID:AB_10603116
- Product name
- Anti-SPOCK1
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human SPOCK1, Gene description: sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1, Alternative Gene Names: SPOCK, testican-1, TIC1, Validated applications: IHC, Uniprot ID: Q08629, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.2 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Proteoglycan SPOCK1 as a Poor Prognostic Marker Promotes Malignant Progression of Clear Cell Renal Cell Carcinoma via Triggering the Snail/Slug-MMP-2 Axis-Mediated Epithelial-to-Mesenchymal Transition
SPOCK1 Is a Novel Transforming Growth Factor-β–Induced Myoepithelial Marker That Enhances Invasion and Correlates with Poor Prognosis in Breast Cancer
Assessment of the stromal contribution to Sonic Hedgehog‐dependent pancreatic adenocarcinoma
Lin Y, Wen Y, Hsiao C, Lai F, Yang S, Yang Y, Ho K, Hsieh F, Hsiao M, Lee W, Chien M
Cells 2023;12(3):352
Cells 2023;12(3):352
SPOCK1 Is a Novel Transforming Growth Factor-β–Induced Myoepithelial Marker That Enhances Invasion and Correlates with Poor Prognosis in Breast Cancer
Castresana J, Fan L, Jeng Y, Lu Y, Lien H
PLOS ONE 2016;11(9):e0162933
PLOS ONE 2016;11(9):e0162933
Assessment of the stromal contribution to Sonic Hedgehog‐dependent pancreatic adenocarcinoma
Damhofer H, Medema J, Veenstra V, Badea L, Popescu I, Roelink H, Bijlsma M
Molecular Oncology 2013;7(6):1031-1042
Molecular Oncology 2013;7(6):1031-1042
No comments: Submit comment
No validations: Submit validation data